Generate QR code
Open Access
Subscription Access
The influence of nutritional support on the conditions of patients with chronic diffuse liver diseases of toxic-alimentary etiology
https://doi.org/10.17021/1992-6499-2025-4-18-31
Abstract
The influence of nutritional support on the condition of patients suffering from chronic diffuse liver diseases of toxic- alimentary origin, including alcoholic liver disease, is being examined. The material for analysis consisted of publications by both domestic and foreign authors, which describe modern strategies of nutritional intervention, their significance in correcting protein-energy deficiency, as well as in the prevention and treatment of malnutrition and sarcopenia. The summarized results of the studies demonstrate that properly organized nutritional therapy contributes to the restoration of liver functional reserves, reduces the frequency and severity of complications, including hepatic encephalopathy, and positively affects the prognosis and quality of life of patients. An analysis of the effectiveness of various approaches was conducted – from therapeutic diets and enteral nutrition to parenteral methods – taking into account their advantages, risks, and metabolic consequences. Based on this review, the authors conclude that nutritional support should be considered an essential component of comprehensive treatment for patients with chronic diffuse liver diseases of toxic- alimentary etiology, and the development of unified standards for its administration is an important task for future clinical studies.
About the Authors
G. V. Komarov
Astrakhan State Medical University
Russian Federation
Russian Federation
Georgii V. Komarov, Assistant Professor of the Department,
Astrakhan.
V. V. Antonyan
Astrakhan State Medical University
Russian Federation
Russian Federation
Vitalina V. Antonyan, Dr. Sci. (Med.), Associate Professor, Head of the Department,
Astrakhan.
A. R. Umerova
Astrakhan State Medical University
Russian Federation
Russian Federation
Adela R. Umerova, Dr. Sci. (Med.), Professor, Head of the Department,
Astrakhan.
O. P. Ostroverkhov
Astrakhan State Medical University
Russian Federation
Russian Federation
Oleg P. Ostroverkhov, Cand. Sci. (Med.), Associate Professor of the Department,
Astrakhan.
References
1. Lazebnik L. B., Radchenko V. G., Golovanova E. V., Zvenigorodskaya L. A., Konev Y. V., Seliverstov P. V., Sitkin S. I., Tkachanko E. I., Avalueva E. B., Aylamazyan E. K., Vlasov N. N., Grinevich V. B., Korniyenko E. A., Novikova V. P., Khoroshinina L. P., Zheskova N. V., Oreshko L. S., Dudanova O. P., Dobrica V. P., Turyueva L. V., Tirikova O. V., Kozlova N. M., Eliseev S. M., Gumerov R. R., Ventsak E. V., Aleshina E. I., Gurova M. M., Goryacheva L. G. Non-alcoholic Fatty Liver Disease: Clinical Features, Diagnosis, Treatment (Guidelines for Therapists, 2nd edition). Ekspertnaya i klinicheskaya gastroenterologiya = Expert and Clinical Gastroenterology. 2017; 138 (2): 22–37 (In Russ.).
2. Tomeno W., Yoneda M., Imaj K., Ogawa Y., Kessoku T., Saito S., Eguchi Y., Nakajima A. Emerging drugs for non-alcoholic steatohepatitis. II Expert Opinion on Emerging Drugs. 2013; 1S (3): 279–290.
3. Bellentani S., Pozatto G. Saccoccio G., Crovatto M., Crocè L.S., Mazzoran L., Masutti F., Cristianini G., Tiribelli C. Clinical course and risk factors of hepatitis C virus related disease in the general population: report from the Dionysos study. Gut. 1999; 44 (3): 874–880.
4. Komova A. G., Maevskaya M. V., Ivashkin V. T. Principles of Effective Diagnosis of Diffuse Liver Diseases at the Outpatient Stage. Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii = Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2014; 24 (6): 36–41 (In Russ.).
5. Tsukanov V. V., Vasyutin A. V., Tonkikh Y. Y. The Burden of Liver Cirrhosis in the Modern World. Doctor.ru. 2021; 20 (4) 21–25 (In Russ.).
6. Kim S. E. Importance of nutritional therapy in the management of intestinal diseases: beyond energy and nutrient supply. Intestinal Research. 2019; 17 (4): 443–454.
7. American Association for the Study of Liver Diseases, European Association for the Study of the Liver. Hepatic Encephalopathy in Chronic Liver Disease: 2014 Practice Guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases. Journal of Hepatology. 2014; 61 (3): 642–659.
8. Popova T. S. Nutritivnaya Podderzhka: Sovremennaya Kontseptsiya Klinicheskogo Pitaniya. Klinicheskoe pitanie i metabolism = Clinical Nutrition and Metabolism. 2020; 1 (1): 5–7 (In Russ.).
9. Mendez-Guerrero O., Carranza-Carrasco A., Chi-Cervera L. A., Torre A., Navarro-Alvarez N. Optimizing Nutrition in Hepatic Cirrhosis: A Comprehensive Assessment and Care Approach. World Journal of Gastroenterology. 2024; 30 (10): 1313–1328.
10. Amodio P., Bemeur C., Butterworth R., Cordoba J., Kato A., Montagnese S., Uribe M., Vilstrup H., Morgan M. Y. The nutritional management of hepatic encephalopathy in patients with cirrhosis: International Society for Hepatic Encephalopathy and Nitrogen Metabolism Consensus. Hepatology. 2013; 58 (1): 325–336.
11. Milovanov Yu. S. Nutritional Status in Patients with Chronic Kidney Disease at the Pre-Dialysis Stage. Vestnik nauchno-tekhnicheskogo razvitiya = Bulletin of Scientific and Technical Development. 2010; 3 (31): 11–24 (In Russ.).
12. Khlynov I. B., Chikunova M. V., Lisovskaya T. V. Efficiency of nutritional support in hepatic cell failure associated with liver cirrhosis. Eksperimentalnaya i klinicheskaya gastroenterologiya = Experimental and Clinical Gastroenterology. 2009; 2: 39–43 (In Russ.).
13. Tandon P., Low G., Mourtzakis M., Zenith L., Myers R. P., Abraldes J. G. A Model to Identify Sarcopenia in Patients With Cirrhosis. Clinical Gastroenterology and Hepatology. 2016; 14 (10): 1473–1480.e3.
14. Kim G., Kang S. H., Kim M. Y., Baik S. K. Prognostic value of sarcopenia in patients with liver cirrhosis: A systematic review and meta-analysis. PLoS One. 2017; 12 (10): e0186990.
15. Chen H. W., Dunn M. A. Muscle at Risk: The Multiple Impacts of Ammonia on Sarcopenia and Frailty in Cirrhosis. Clinical and Translational Gastroenterology. 2016; 7 (5): e170.
16. Dasarathy S. Consilience in sarcopenia of cirrhosis. Journal of Cachexia, Sarcopenia and Muscle. 2012; 3 (4): 225–237.
17. Ganda O. P., Ruderman N. B. Muscle nitrogen metabolism in chronic hepatic insufficiency. Metabolism. 1976; 25 (4): 427–435.
18. Lockwood A. H., McDonald J. M., Reiman R. E., Gelbard A. S., Laughlin J. S., Duffy T. E., Plum F. The dynamics of ammonia metabolism in man. Effects of liver disease and hyperammonemia. Journal of Clinical Investigation. 1979; 63 (3): 449–460.
19. Noiret L., Baigent S., Jalan R. Arterial ammonia levels in cirrhosis are determined by systemic and hepatic hemodynamics, and by organ function: a quantitative modelling study. Liver International. 2014; 34 (6): e45–e55.
20. Dasarathy S., Hatzoglou M. Hyperammonemia and proteostasis in cirrhosis. Current Opinion in Clinical Nutrition and Metabolic Care. 2018; 21 (1): 30–36.
21. Egorov D. V. Osobennosti statusa pitaniya u bolnykh s dekompensirovannym tsirrozom pecheni = Nutritional Status Characteristics in Patients with Decompensated Liver Cirrhosis. Abstract of thesis of Doctor of Medical Sciences. Saint Petersburg; 2010: 129 p. (In Russ.).
22. Gavrilenko D. I., Gavrilenko T. E., Rodina E. V. Nutritional Disorders in Chronic Liver Diseases. Part 1. Diagnostic Methods for Nutritional Disorders. Vestnik Vitebskogo gosudarstvennogo meditsinskogo universiteta = Bulletin of the Vitebsk State Medical University. 2023; 22 (1): 19–30 (In Russ.).
23. Hanai T., Shiraki M., Nishimura K., Ohnishi S., Imai K., Suetsugu A., Takai K., Shimizu M., Moriwaki H. Usefulness of carnitine supplementation for the complications of liver cirrhosis. Nutrients. 2020; 12 (7): 1915.
24. Osipenko M. F., Zhuk E. A. Nutritional support for chronic liver diseases. Eksperimentalnaya i klinicheskaya gastroenterologiya = Experimental and Clinical Gastroenterology. 2020; 10 (182): 101–106 (In Russ.).
25. Tadokoro T., Morishita A., Himoto T., Masaki T. Nutritional support for alcoholic liver disease. Nutrients. 2023;15 (6): 1360.
26. Younossi Z. M., Koenig A. B., Abdelatif D., Fazel Y., Henry L., Wymer M. Global epidemiology of nonalcoholic fatty liver disease: Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016; 64 (1): 73–84.
27. Nichik T. E., Belova S. N., Burmistrova N. V., Kolobkova Yu. A., Savel'eva L. S., Erofeeva I. S., Popova A. I., Pashchenko P. S., Berezovskaya N. V., Klyushina A. I. Innovative Technologies for Screening Malnutrition Syndrome (Literature Review). Sovremennye problemy zdravookhraneniya i meditsinskoy statistiki = Modern Problems of Health Care and Medical Statistics. 2020; 1: 53–68 (In Russ.).
28. Puri P., Choudhury A., Sharma B. C., Kumar M., Maiwall R., Sarin S. K. Nutrition in chronic liver disease: Consensus statement of the Indian National Association for Study of the Liver. Journal of Clinical and Experimental Hepatology. 2021;11 (1): 97–143.
29. Singal A. K., Bataller R., Ahn J., Kamath P. S., Shah V. H. ACG Clinical Guideline: Malnutrition and Nutritional Recommendations in Liver Disease. American Journal of Gastroenterology. 2025; 120 (5): 950–972.
30. European Association for the Study of the Liver. EASL Clinical Practice Guidelines on Nutrition in Chronic Liver Disease. Journal of Hepatology. 2019; 70 (1): 172–193.
31. Espina S., Casas-Deza D., Bernal-Monterde V., Domper-Arnal M. J., García-Mateo S., Lué A. Evaluation and Management of Nutritional Consequences of Chronic Liver Diseases. Nutrients. 2023; 15 (15): 3487. doi: 10.3390/nu15153487.
32. Sobhrakhshankhah E., Farahmand M., Hasan Rashedi M., Shahinfar H., Shab-Bidar S., Dinari S., Doustmohammadian A. Efficacy of Different Nutrition Interventions on Sarcopenia in Patients with Cirrhosis: a Systematic Review and Network Meta-analysis. BMC Nutrition. 2025; 11 (1): 39.
33. Okubo H., Ando H., Nakadera E., Ikejima K., Shiina S., Nagahara A. Levocarnitine supplementation Suppresses Lenvatinib-Related Sarcopenia in Hepatocellular Carcinoma Patients: Results of a Propensity Score Analysis. Nutrients. 2021; 13 (12): 4428.
34. Lattanzi B., Bruni A., Di Cola S., Molfino A., De Santis A., Muscaritoli M., Merli M. The Effects of 12Week Beta-hydroxy-beta-methylbutyrate Supplementation in Patients with Liver Cirrhosis: Results from a Randomized Controlled Single-Blind Pilot Study. Nutrients. 2021; 13 (7): 2296.
35. Hsu H. C., Chang W. K., Chen Y. C., Lin S. Y., Yang S. S., Lin H. H. Effects of Exercise and Nutrition in Improving Sarcopenia in Liver Cirrhosis Patients: a Systematic Review and Meta-analysis. Hepatobiliary Surgery and Nutrition. 2025; 14 (1): 33–48.
36. Tandon P., Ismond K. P., Riess K., Duarte-Rojo A., Al-Judaibi B., Dunn M. A. Sarcopenia and Frailty in Decompensated Cirrhosis. Journal of Hepatology. 2021; 75, 1 (Suppl. 1): S147–S162.
37. Hernández-Conte E., Mantuano P., Boccanegra B., Imbrici P., Dinoi G., Lenti R., Cappellari O., Cappetta D., De Angelis, A., Berrino L., Gordish-Dressman H., Bianchini G., Aramini A., Allegretti M., Liantonio A., De Luca A. Adding Branched-Chain Amino Acids to an Enhanced Standard-of-care Treatment Improves Muscle Mass of Cirrhotic Patients with Sarcopenia: a Placebo-Controlled Trial. American Journal of Gastroenterology. 2021; 116 (11): 2241–2249.
38. Chen L. K., Woo J., Assantachai P., Auyeung T. W., Chou M. Y., Iijima K., Jang H. C., Kang L., Kim M., Kim S., Kojima T., Kuzuya M., Lee J. S. W., Lee S. Y., Lee W. J., Lee Y., Liang C. K., Lim J. Y., Lim W. S., Peng L. N., Arai H. Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. Journal of the American Medical Directors Association. 2020; 21 (3): 300–307.e2.
39. Zaccherini G., Tufoni M., Bernardi M. Albumin Administration is Efficacious in the Management of Patients with Cirrhosis: a Systematic Review of the Literature. Hepatic Medicine: Evidence and Research. 2020; 12: 153–172.
40. Boesiger F., Poggioli A., Netzhammer C., Bretscher C., Kaegi-Braun N., Tribolet P., Wunderle C., Kutz A., Lobo D. N., Stanga Z., Mueller B., Schuetz P. Changes in Serum Albumin Concentrations Over 7 Days in Medical Inpatients with and Without Nutritional Support: a Secondary Post-hoc Analysis of a Randomized Clinical Trial. European Journal of Clinical Nutrition. 2023; 77 (10): 989–997.
41. Ruiz-Margáin A., Macías-Rodríguez R. U., Ríos-Torres S. L., Román-Calleja B. M., Méndez-Guerrero O., Rodríguez-Córdova P. Dietary Management and Supplementation with Branched-Chain Amino Acids in Cirrhosis of the Liver. Revista de Gastroenterología de México (English Edition). 2018; 83 (4): 424–433.
42. Kamran U., Towey J., Khanna A., Chauhan A., Rajoriya N., Holt A. Nutrition in Alcohol-related Liver Disease: Physiopathology and Management. World Journal of Gastroenterology. 2020; 26 (22): 2916–2930.
43. Antar R., Wong P., Ghali P. A Meta-analysis of Nutritional Supplementation for Management of Hospitalized Alcoholic Hepatitis. Canadian Journal of Gastroenterology. 2012; 26 (7): 463–467.
44. Fialla A. D., Israelsen M., Hamberg O., Krag A., Gluud L. L. Nutritional Therapy in Cirrhosis or Alcoholic Hepatitis: a Systematic Review and Meta-analysis. Liver International. 2015; 35 (9): 2072–2078.
45. Żalikowska-Gardocka M., Przybyłkowski A. Review of Parenteral Nutrition-associated Liver Disease. Clinical and Experimental Hepatology. 2020; 6 (2): 65–73.
46. Park J. W., Yoo J. J., Lee D. H., Chang Y., Jo H., Cho Y. Y., Lee S., Kim L. Y., Jang J. Y. Korean Association for the Study of the Liver. Evolving Epidemiology of Non-alcoholic Fatty Liver Disease in South Korea: Incidence, Prevalence, Progression, and Healthcare Implications from 2010 to 2022. The Korean Journal of Internal medicine. 2024; 39 (6): 931–944. doi: 10.3904/kjim.2024.164.
47. Lakananurak N., Tienchai K. Incidence and Risk Factors of Parenteral Nutrition-Associated Liver Disease in Hospitalized Adults: a Prospective Cohort Study. Clinical Nutrition ESPEN. 2019; 34: 81–86.
48. Park J. W., Kim T. H., Kim H. J., Jang J. Y., Park Y. S., Lee J. E. Parenteral Nutrition-induced Liver Function Complications: Incidence, Risk Factors, and Prognosis. Journal of Clinical Medicine. 2025; 14 (4): 1220.
49. Alluri S., Subedi R., Shen W., Ghaffar T., Chaudry Z., Chen H. Patterns and Predictors of Outcomes in Total Parenteral Nutrition Associated Liver Disease. American Journal of Gastroenterology. 2024; 119 (10S): S1386–S1386.
50. Sorokina E. Yu. Acute Liver Disorders in Intensive Care Unit Patients and Metabolic Therapy Methods. Meditsina neotlozhnykh sostoyaniy = Emergency Medicine. 2015; 8 (71): 35–45 (In Russ.).
51. Rose C., Michalak A., Pannunzio M., Chatauret N., Rambaldi A., Butterworth R. F. L-Ornithine-LAspartate in Experimental Portal-Systemic Encephalopathy: Therapeutic Efficacy and Mechanism of Action. Metabolic Brain Disease. 1998; 13 (2): 147–157.
52. Schmid M., Peck-Radosavljevic M., König F., Mittermaier C., Gangl A., Ferenci P. A Double-blind, Randomized, Placebo-Controlled Trial of Intravenous L-Ornithine-L-aspartate on Postural Control in Patients with Cirrhosis. Liver International. 2010; 30 (4): 574–582.
53. Plotnikova E. Yu. The role of L-ornithine-L-aspartate in the Complex Treatment of Patients with Hyperammonemia. Klinicheskie perspektivy gastroenterologii, gepatologii = Clinical Perspectives of Gastroenterology, Hepatology. 2013; 2: 41–49.
54. Laptev V. V., Ovsyannikov V. L., Nepomnyashchikh G. I., Savchenko A. P., Makarenko A. I., Kurenkov A. L. Use of the Drug “Gepa-Merz” in Mechanical Jaundice of Non-neoplastic Origin. Annaly khirurgicheskoy gepatologii = Annals of Surgical Hepatology. 2008; 13 (4): 106–111.
Review
For citations:
Komarov G.V., Antonyan V.V., Umerova A.R., Ostroverkhov O.P. The influence of nutritional support on the conditions of patients with chronic diffuse liver diseases of toxic-alimentary etiology. Astrakhan medical journal. 2025;20(4):18-31. (In Russ.) https://doi.org/10.17021/1992-6499-2025-4-18-31
Views:
16
Email this article 